3-(2-Chloroethoxy)-N-(2-pyridylmethyl)propanamide | 1414942-23-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 3-(2-Chloroethoxy)-N-(2-pyridylmethyl)propanamide
• 英文别名: 3-(2-chloroethoxy)-N-(pyridin-2-ylmethyl)propanamide
• CAS: 1414942-23-6
• 化学式: C₁₁H₁₅ClN₂O₂
• 分子量: 242.705
• InChiKey: YNXZXMIEPRKISC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  16
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  51.2
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  氯-一聚乙二醇-酸 在 氯化亚砜 、 sodium hydroxide 作用下， 以 二氯甲烷 、 水 为溶剂， 生成 3-(2-Chloroethoxy)-N-(2-pyridylmethyl)propanamide
  参考文献：
  名称：

  NEW I-ARYLPIPERAZINIC LIGANDS OF 5-HT7 RECEPTOR AND USE THEREOF

  摘要：

  该发明涉及一类新的化合物，能够高亲和力和选择性地抑制5-HT7受体。该发明还涉及将这类化合物用作药物，用于治疗和预防中枢神经系统与5-HT7受体相关的疾病。该发明还涉及同位素标记的化合物，用于体内诊断或成像5-HT7状况。

  公开号：

  US20140086834A1

文献信息

• [EN] NEW 1-ARYLPIPERAZINIC LIGANDS OF 5-HT7 RECEPTOR AND USE THEREOF<br/>[FR] NOUVEAUX LIGANDS 1-ARYLPIPÉRAZINIQUES DE RÉCEPTEUR 5-HT7 ET UTILISATION DE CEUX-CI
  申请人：UNIV BARI

  公开号：WO2012159662A1

  公开（公告）日：2012-11-29

  The invention relates to a new class of compounds able to inhibit with high affinity and selectivity the 5-HT7 receptor. The invention also relates to the utilization of such compounds as medicaments useful in the treatment and prevention of 5-HT7 receptor relating disorders of the central nervous system. The invention also relates to the isotopically labeled compounds for use in vivo diagnosis or imaging of a 5-HT7 condition.

  这项发明涉及一类新的化合物，能够以高亲和力和选择性抑制5-HT7受体。该发明还涉及将这类化合物用作药物，用于治疗和预防中枢神经系统与5-HT7受体相关的疾病。该发明还涉及同位素标记的化合物，用于体内诊断或成像5-HT7状况。
• I-arylpiperazinic ligands of 5-HT7 receptor and use thereof
  申请人：Leopoldo Marcello

  公开号：US09260400B2

  公开（公告）日：2016-02-16

  The invention relates to a new class of compounds able to inhibit with high affinity and selectivity the 5-HT7 receptor and having the following formula IV: wherein W is O; K, L, M and Q is CH or nitrogen; R1 is hydrogen; R2 is hydrogen; and Ar is an aromatic ring with the following formula: wherein X, Y and Z is CH; and R3 is a five- or six-membered ring selected from the group consisting of:

  本发明涉及一种新的化合物类别，能够高亲和力和选择性地抑制5-HT7受体，并具有以下公式IV：其中W为O；K、L、M和Q为CH或氮；R1为氢；R2为氢；而Ar为具有以下公式的芳香环：其中X、Y和Z为CH；而R3为从以下组中选择的五元或六元环：
• New 1-arylpiperazinic ligands of 5-HT7 receptor and use thereof
  申请人：Università degli Studi di Bari "Aldo Moro"

  公开号：EP2816037A2

  公开（公告）日：2014-12-24

  The invention relates to a new class of compounds able to inhibit with high affinity and selectivity the 5-HT7 receptor. The invention also relates to the utilization of such compounds as medicaments useful in the treatment and prevention of 5-HT7 receptor relating disorders of the central nervous system. The invention also relates to the isotopically labeled compounds for use in vivo diagnosis or imaging of a 5-HT7 condition.

  本发明涉及一类能以高亲和力和选择性抑制 5-HT7 受体的新型化合物。本发明还涉及将此类化合物用作治疗和预防与 5-HT7 受体有关的中枢神经系统疾病的药物。本发明还涉及用于 5-HT7 病症体内诊断或成像的同位素标记化合物。
• US9260400B2
  申请人：——

  公开号：US9260400B2

  公开（公告）日：2016-02-16
• NEW I-ARYLPIPERAZINIC LIGANDS OF 5-HT7 RECEPTOR AND USE THEREOF
  申请人：UNIVERSITA' DEGLI STUDI DI BARI ''ALDO MORO''

  公开号：US20140086834A1

  公开（公告）日：2014-03-27

  The invention relates to a new class of compounds able to inhibit with high affinity and selectivity the 5-HT7 receptor. The invention also relates to the utilization of such compounds as medicaments useful in the treatment and prevention of 5-HT7 receptor relating disorders of the central nervous system. The invention also relates to the isotopically labeled compounds for use in vivo diagnosis or imaging of a 5-HT7 condition.

  该发明涉及一类新的化合物，能够高亲和力和选择性地抑制5-HT7受体。该发明还涉及将这类化合物用作药物，用于治疗和预防中枢神经系统与5-HT7受体相关的疾病。该发明还涉及同位素标记的化合物，用于体内诊断或成像5-HT7状况。